E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Type 2 Diabetes Mellitus |
Type 2 Diabetes |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary objective: To assess the long-term effects (i.e. after 8-week drug exposure) of the GLP-1RA lixisenatide versus insulin glulisine on renal hemodynamics (glomerular filtration rate/effective renal plasma flow) in patients with type 2 diabetes |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives: renal damage, renal tubular function, blood pressure |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Type 2 diabetes mellitus •Caucasian •Both genders (females must be post-menopausal; no menses >1 year) •Age: 35 - 75 years •BMI: 25 - 40 kg/m2 •HbA1c: 6.5 - 10% DCCT (48 - 86 mmol/mol International Federation of Clinical Chemistry) •Stable treatment with basal insulin glargine and metformin or basal insulin glargine alone •Fasting plasma glucose (FPG) <10 mmol/L or the use of >50 units of basal insulin glargine •Hypertension should be under control, i.e. <140/90 mmHg, and treated with a RAAS-interfering agent (ACE-I or ARB) for at least 3 months. •Albuminuria should be treated with a RAAS-interfering agent (ACE-I or ARB) for at least 3 months. •Written informed consent
|
|
E.4 | Principal exclusion criteria |
•Current/chronic use of the following medication: TZD, SU derivative, GLP-1RA, DPP-4I, glucocorticoids, immune suppressants, antimicrobial agents, chemotherapeutics antipsychotics, tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). Subjects on diuretics, will only be excluded when these drugs cannot be stopped for the duration of the study. •Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) will not be allowed, unless used as incidental medication (1-2 tablets) for non-chronic indications (i.e. sports injury, head-ache or back ache). However, no such drugs can be taken within a time-frame of 2 weeks prior to renal-testing •Hypoglycemia unawareness based on investigator judgment •History of severe hypoglycemia that required emergency hospital treatment within 3 months prior to screening •Estimated GFR <60 mL/min/1.73m2 (determined by the Modification of Diet in Renal Disease (MDRD) study equation) •Pregnancy •Current urinary tract infection and active nephritis •Recent (<6 months) history of cardiovascular disease, including: oAcute coronary syndrome oChronic heart failure (New York Heart Association grade II-IV) oStroke or transient ischemic neurologic disorder •Current atrial fibrillation •Complaints compatible with or established gastroparesis, neurogenic bladder and/or incomplete bladder emptying (as determined by ultrasonic bladder scan) •Active liver disease or a 3-fold elevation of liver enzymes (aspartate aminotransferase (AST)/alanine aminotransferase (ALT)) at screening •History of or actual pancreatic disease •History of or actual malignancy •History of or actual severe mental disease •Substance abuse (alcohol: defined as >4 units/day) •Allergy to any of the agents used in the study (i.e. GLP-1RA, inulin, metacresol (component lixisenatide and insulin glulisine), PAH, latex (component of PAH vial stopper)) •Individuals who are investigator site personnel, directly affiliated with the study, or are immediate (spouse, parent, child, or sibling, whether biological or legally adopted) family of investigator site personnel directly affiliated with the study •Inability to understand the study protocol or give informed consent
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
To assess changes from baseline following 8-week treatment with a GLP-1RA versus a single dose of insulin on renal hemodynamics measured as: •Glomerular filtration rate (measured by the inulin-clearance technique) •Effective renal plasma flow (measured by the para-aminohippurate acid clearance technique) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Renal hemodynamics are assessed at baseline and after 8 weeks of treatment |
|
E.5.2 | Secondary end point(s) |
To assess changes from baseline following 8-week treatment with a GLP-1RA versus a single dose of insulin on: •Renal damage, measured by urine biomarkers as: oUrinary albumin excretion (Glomerular) oNeutrophil gelatinase-associated lipocalin and Kidney injury molecule-1 (Tubular) •Renal tubular function, measured as: oFractional sodium-, potassium-, chloride-, calcium-, magnesium-, phosphate- and urea excretion oUrine osmolality •Systolic blood pressure, diastolic blood pressure and mean arterial pressure (measured by oscillometric blood pressure device)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary endpoints are assessed at baseline and after 8 weeks of treatment |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Mechanistic: the aim is to assess changes in renal physiology using a GLP-1RA versus an insulin analog |
Mechanistisch: het doel is om veranderingen te bepalen in renale fysiologie tussen een GLP-1RA versus een insuline analoog |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 0 |